<DOC>
	<DOCNO>NCT02933788</DOCNO>
	<brief_summary>This study evaluate suitable treatment prevention vascular complication diabetes patent high cardiovascular risk group compare platelet aggregation inhibitory effect aspirin cilostazol .</brief_summary>
	<brief_title>Effect aSpirin Versus CilOstazol Inhibition Antiplatelet aggRegaTion Type 2 DM Patients</brief_title>
	<detailed_description>Diabetes dangerous disease high risk vascular complication . Thus , prevent vascular complication , antithrombotic drug may administer . Representative antithrombotic agent aspirin cilostazol . However , recent study suggest aspirin sufficient effect prevent vascular complication diabetes . For reason , report antithrombotic effect aspirin fall diabetes patient , so-called 'aspirin resistance . On hand , cilostazol use control drug inhibits atherosclerosis diabetes patient study Asia include Korea , effective inhibit risk various cardiovascular disease . Therefore , cilostazol likely use drug substitute aspirin therapy .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<criteria>Who one follow risk factor : Family history cardiovascular disease Hypertension Smoking History Dyslipidemia Albuminuria Who high risk bleeding Who stop take Cilostazol Aspirin randomize period 1months Who never take drug Type 1 diabetes mellitus , gestational diabetes Who history macrovascular complication include cardiovascular disease , cerebrovascular disease peripheral vascular disease</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>cardiovascular disease</keyword>
	<keyword>atherosclerosis</keyword>
</DOC>